Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

The United States Food and Drug Administration recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Pharmacokinetic data confirm equivalent drug exposure in this population as that found in adults during clinical trials. The efficacy and safety of these drugs has been shown in clinical trials.

Original languageEnglish (US)
Pages (from-to)447-451
Number of pages5
JournalDrugs of Today
Volume53
Issue number8
DOIs
StatePublished - Aug 1 2017

Keywords

  • Children
  • Hepatitis C
  • Ledipasvir/sofosbuvir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children'. Together they form a unique fingerprint.

  • Cite this